Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

Mankind Pharma Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 1.14300
forwardPE 34.04672
debtToEquity 53.89200
earningsGrowth -0.24000
revenueGrowth 0.20200
grossMargins 0.69782
operatingMargins 0.18920
trailingEps 42.36000
forwardEps 61.90318

Mankind Pharma Limited's current ratio 1.143, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, Mankind Pharma Limited can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
MANKIND's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
Mankind Pharma Limited's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.
MANKIND's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that MANKIND is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

The stock price of MANKIND has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


Analysts' buy bias toward MANKIND suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, MANKIND is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.